文献速递生殖医学

体外受精实验室中的附加干预:附加干预措施的证据何在?

Adjuncts in the IVF laboratory: where is the evidence for 'add-on' interventions?
PubMed 文献 · Hum Reprod · 2017-01-01

该文讨论全球体外受精(IVF)实验室中常规提供并收费的多种附加治疗与检测,包括胚胎胶与黏附化合物、精子DNA碎片检测、时差成像、胚胎植入前遗传学筛查、线粒体DNA负荷测量和辅助孵化。作者指出这些附加干预缺乏支持其提高活产率的临床证据,并强调任何声称提高活产率的新技术应先经动物模型、临床试验和随机对照试验验证安全性与有效性,再考虑作为常规应用,且需长期随访。结论是需要稳健研究确认附加治疗或检测的安全性和有效性后方可常规提供。

要点

  • IVF患者常被提供并收费的附加干预缺乏支持其提高活产率的临床证据。
  • 任何声称提高活产率的新技术应先经动物模型、临床试验和随机对照试验验证。
  • 附加干预仅在随机对照试验验证安全有效且应用于相似患者群体时才应考虑为常规。

核心结论

  • 需要稳健研究确认任何附加治疗或检测的安全性和有效性,之后方可常规提供给IVF患者。
  • 任何声称提高活产率的新IVF技术应先经适当动物模型、临床试验和随机对照试验验证安全有效,再考虑作为常规。

研究设计与样本

  • 本文为综述,讨论全球IVF实验室中目前提供的多种附加治疗与检测的安全性及提高活产率的有效性证据。

主要发现

  • 目前有众多附加治疗在缺乏循证医学证据的情况下被使用,且常额外收费。
  • 部分附加技术在随机对照试验显示无效后最终被撤出临床。
  • 文中讨论的附加干预包括胚胎胶与黏附化合物、精子DNA碎片检测、时差成像、胚胎植入前遗传学筛查、线粒体DNA负荷测量和辅助孵化。

临床怎么用

  • 作者认为任何附加治疗或检测在常规提供给IVF患者前,需稳健研究确认其安全性和有效性。
  • 作者认为新技术仅在随机对照试验验证安全有效且应用于与试验相似的患者群体时,才可考虑为常规。
  • 作者认为即使如此,仍需进一步儿科和长期随访研究 examining 该程序的长期安全性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Globally, IVF patients are routinely offered and charged for a selection of adjunct treatments and tests or 'add-ons' that they are told may improve their chance of a live birth, despite there being no clinical evidence supporting the efficacy of the add-on. Any new IVF technology claiming to improve live birth rates (LBR) should, in most cases, first be tested in an appropriate animal model, then in clinical trials, to ensure safety, and finally in a randomized controlled trial (RCT) to provide high-quality evidence that the procedure is safe and effective. Only then should the technique be considered as 'routine' and only when applied to the similar patient population as those studied in the RCT. Even then, further pediatric and long-term follow-up studies will need to be undertaken to examine the long-term safety of the procedure. Alarmingly, there are currently numerous examples where adjunct treatments are used in the absence of evidence-based medicine and often at an additional fee. In some cases, when RCTs have shown the technique to be ineffective, it is eventually withdrawn from the clinic. In this paper, we discuss some of the adjunct treatments currently being offered globally in IVF laboratories, including embryo glue and adherence compounds, sperm DNA fragmentation, time-lapse imaging, preimplantation genetic screening, mitochondria DNA load measurement and assisted hatching. We examine the evidence for their safety and efficacy in increasing LBRs. We conclude that robust studies are needed to confirm the safety and efficacy of any adjunct treatment or test before they are offered routinely to IVF patients.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Harper J, Jackson E, Sermon K, et al. Adjuncts in the IVF laboratory: where is the evidence for 'add-on' interventions? Hum Reprod. 2017. PMID: 28158511. doi:10.1093/humrep/dex004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。